Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. (S)(S) 200.80(b)(4), 200.83 and 240.24b-2 COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENT Collaborative Development and Marketing Agreement TABLE OF CONTENTS...Collaborative Development and Marketing Agreement • November 12th, 2002 • Dendreon Corp • Pharmaceutical preparations • New York
COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENTCollaborative Development and Marketing Agreement • September 13th, 2004 • Palatin Technologies Inc • Pharmaceutical preparations • New York
This COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENT is entered into as of August 12, 2004 (the “Effective Date”), by and between PALATIN TECHNOLOGIES, INC., a Delaware corporation having an address of Cedar Brook Corporate Center, 4C Cedar Brook Drive, Cranbury, New Jersey 08512 (“Palatin”) and KING PHARMACEUTICALS, INC., a Tennessee corporation having an address of 501 Fifth Avenue, Bristol, Tennessee 37620, (“King”). Each of King and Palatin is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
EXHIBIT 10.28 COLLABORATIVE DEVELOPMENT AND MARKETING AGREEMENTCollaborative Development and Marketing Agreement • January 10th, 2002 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
